News

PharmaMar submitted the above mentioned application for the antitumor drug of marine origin, Aplidin, in combination with dexamethasone given the positive results obtained from the ADMYRE study. Plitidepsin

Study 311 is a global multicenter, single-arm Phase III clinical study of perampanel in approximately 160 patients (ages 4 to less than 12 years) with inadequately controlled partial-onset

Located in Mainz, Ganymed was established in 2001. It is engaged in the development of a new class of immunotherapeutic cancer drugs called ideal monoclonal antibodies (IMABs). The

Motus is a subsidiary of Rhythm Holding, which also owns Rhythm Pharmaceuticals. The acquisition will include Motus’ lead drug candidate relamorelin (RM-131), a ghrelin agonist being developed for

Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Inositec’s

The study met its primary endpoint in this cohort as measured by a change in total chloride response following 4 weeks of treatment with QR-010. In the compound

In April 2015, the FDA granted orphan drug status to ADS-5102 for this indication.  Adamas Pharmaceuticals chairman and CEO Gregory Went said: "The ADS-5102 NDA submission represents a major milestone

The phase III randomized, double-blind, parallel arm, multiple dose, active comparator study also met secondary endpoints. The study included 645 patients diagnosed with moderate to severe active RA

Patients who received apatorsen treatment experienced a 20% reduction in risk of death, compared to patients receiving docetaxel alone (HR=.80; 95% CI: 0.65-0.98; p=0.078). The primary analysis was